Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effects of growth hormone status on circulating levels of vascular growth factors

J.V. Silha, M. Krsek, V. Hana, J. Marek, V. Weiss, J. Jezkova, M. Rosicka, Z. Jarkovska, L.J. Murphy

. 2005 ; 63 (1) : 79-86.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13014843

Grantová podpora
NB7569 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Část
Zdroj

E-zdroje Online Plný text

NLK Wiley Online Library (archiv) od 1997-01-01 do 2012-12-31

BACKGROUND: Vascular growth factors are important not only in angiogenesis but also for the maintenance of normal endothelial integrity and function. Elevated levels of vascular endothelial growth factor (VEGF), angiopoietin-2, hepatocyte growth factor (HGF), endostatin and angiogenin have been associated with endothelial dysfunction and atherosclerosis. Both acromegaly and growth hormone deficiency (GHD) are associated with endothelial dysfunction and changes in blood vessel morphology. AIM: To investigate the effect of GH status on the circulating levels of angiogenic factors. DESIGN: We measured the levels of six endothelial growth modulators, four angiogenic growth factors and two inhibitors of angiogenesis in 35 untreated acromegalics, 36 untreated GH-deficient subjects and 101 normal control subjects. Fifteen GH-deficient subjects were also studied before and 1 year after treatment with GH. RESULTS: Mean angiogenin concentrations were increased in acromegaly and decreased in GH-deficient subjects compared to control subjects. Endostatin levels showed a similar pattern although the elevated levels in acromegalic subjects did not achieve statistical significance. Angiogenin and endostatin levels both correlated significantly with IGF-I levels (R = 0.61, P < 0.001 and R = 0.22, P < 0.01, respectively). The relationship between angiogenin and IGF-I levels remained significant even after correction for gender, age, body mass index (BMI) and insulin resistance. There were no significant differences in the levels of HGF, VEGF, VEGF-C or angiopoietin-2 between the three groups. VEGF-D levels were elevated in both acromegalic and GH-deficient male subjects. A similar pattern was apparent in female subjects. After GH treatment, a significant reduction in VEGF-D levels and a significant rise in endostatin levels were observed in GH-deficient subjects. A nonsignificant increase in angiogenin levels was also observed. CONCLUSION: These data indicate that significant perturbations in the levels of vascular growth modulators are present in both acromegaly and GHD. While changes in endostatin and angiogenin levels appear to correlate with IGF-I levels, VEGF-D levels show similar perturbations in both acromegaly and GHD. Further studies are required to determine the relationship of the perturbations to endothelial dysfunction in these conditions.

000      
00000naa a2200000 a 4500
001      
bmc13014843
003      
CZ-PrNML
005      
20190104125501.0
007      
ta
008      
130417s2005 enk f 000 0|eng||
009      
AR
035    __
$a (PubMed)15963066
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a enk
100    1_
$a Silha, J.V. $u Department of Physiology and Internal Medicine, University of Manitoba, Winnipeg, Canada.
245    14
$a The effects of growth hormone status on circulating levels of vascular growth factors / $c J.V. Silha, M. Krsek, V. Hana, J. Marek, V. Weiss, J. Jezkova, M. Rosicka, Z. Jarkovska, L.J. Murphy
520    9_
$a BACKGROUND: Vascular growth factors are important not only in angiogenesis but also for the maintenance of normal endothelial integrity and function. Elevated levels of vascular endothelial growth factor (VEGF), angiopoietin-2, hepatocyte growth factor (HGF), endostatin and angiogenin have been associated with endothelial dysfunction and atherosclerosis. Both acromegaly and growth hormone deficiency (GHD) are associated with endothelial dysfunction and changes in blood vessel morphology. AIM: To investigate the effect of GH status on the circulating levels of angiogenic factors. DESIGN: We measured the levels of six endothelial growth modulators, four angiogenic growth factors and two inhibitors of angiogenesis in 35 untreated acromegalics, 36 untreated GH-deficient subjects and 101 normal control subjects. Fifteen GH-deficient subjects were also studied before and 1 year after treatment with GH. RESULTS: Mean angiogenin concentrations were increased in acromegaly and decreased in GH-deficient subjects compared to control subjects. Endostatin levels showed a similar pattern although the elevated levels in acromegalic subjects did not achieve statistical significance. Angiogenin and endostatin levels both correlated significantly with IGF-I levels (R = 0.61, P < 0.001 and R = 0.22, P < 0.01, respectively). The relationship between angiogenin and IGF-I levels remained significant even after correction for gender, age, body mass index (BMI) and insulin resistance. There were no significant differences in the levels of HGF, VEGF, VEGF-C or angiopoietin-2 between the three groups. VEGF-D levels were elevated in both acromegalic and GH-deficient male subjects. A similar pattern was apparent in female subjects. After GH treatment, a significant reduction in VEGF-D levels and a significant rise in endostatin levels were observed in GH-deficient subjects. A nonsignificant increase in angiogenin levels was also observed. CONCLUSION: These data indicate that significant perturbations in the levels of vascular growth modulators are present in both acromegaly and GHD. While changes in endostatin and angiogenin levels appear to correlate with IGF-I levels, VEGF-D levels show similar perturbations in both acromegaly and GHD. Further studies are required to determine the relationship of the perturbations to endothelial dysfunction in these conditions.
590    __
$a bohemika - dle Pubmed
650    02
$a akromegalie $x krev $x patofyziologie $7 D000172
650    02
$a dospělí $7 D000328
650    12
$a látky indukující angiogenezi $x krev $7 D043925
650    02
$a inhibitory angiogeneze $x krev $7 D020533
650    02
$a angiopoetin-2 $x krev $7 D042702
650    02
$a endostatiny $x krev $7 D043169
650    02
$a ženské pohlaví $7 D005260
650    02
$a hepatocytární růstový faktor $x krev $7 D017228
650    02
$a lidský růstový hormon $x fyziologie $x nedostatek $7 D019382
650    02
$a lidé $7 D006801
650    02
$a insulinu podobný růstový faktor I $x analýza $7 D007334
650    02
$a mužské pohlaví $7 D008297
650    02
$a menopauza $x fyziologie $7 D008593
650    02
$a lidé středního věku $7 D008875
650    02
$a pankreatická ribonukleasa $x krev $7 D012259
650    02
$a sexuální faktory $7 D012737
650    02
$a vaskulární endoteliální růstový faktor A $x krev $7 D042461
650    02
$a vaskulární endoteliální růstový faktor C $x krev $7 D042582
650    02
$a vaskulární endoteliální růstový faktor D $x krev $7 D042643
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kršek, Michal $7 xx0046428 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hána, Václav, $d 1956- $7 xx0018430 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Marek, Josef, $d 1936-2019 $7 nlk19990073526 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Weiss, Vladimír. $7 xx0185340 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Ježková, Jana $7 xx0074177 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Rosická, Martina $7 xx0061797 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Jarkovská, Zuzana $7 xx0056683 $u Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Murphy, L.J. $u Department of Physiology and Internal Medicine, University of Manitoba, Winnipeg, Canada.
773    0_
$t Clinical Endocrinology $x 0300-0664 $g Roč. 63, č. 1 (2005), s. 79-86 $p Clin Endocrinol (Oxf) $w MED00009474
910    __
$a ABA008 $b B 1409 $y 3 $z 0
990    __
$a 20130417133503 $b ABA008
991    __
$a 20190104125657 $b ABA008
999    __
$a ok $b bmc $g 977874 $s 813149
BAS    __
$a 3
BMC    __
$a 2005 $b 63 $c 1 $d 79-86 $i 0300-0664 $m Clinical endocrinology $x MED00009474 $n Clin Endocrinol (Oxf)
GRA    __
$a NB7569 $p MZ0
LZP    __
$a NLK 2013-04/lpbo

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...